Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells

Journal of Immunotherapy

Volumn 31, Issue 5, 2008, Pages 491-499

  Shurin, Galina V ^a,b   Tourkova, Irina L ^a   Shurin, Michael R ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapeutic agents; Dendritic cells; Rho GTPases

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; BLEOMYCIN; BLEOMYCIN SULFATE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DOXORUBICIN; FLUTAMIDE; METHOTREXATE; MITOMYCIN C; PACLITAXEL; RAC PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOE GUANINE NUCLEOTIDE BINDING PROTEIN; TAMOXIFEN; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG; VINBLASTINE; VINBLASTINE SULFATE; VINCRISTINE; VINCRISTINE SULFATE;

ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENDRITIC CELL; DRUG MECHANISM; ENZYME ACTIVITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; ANIMAL; CELL CULTURE; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; DENDRITIC CELLS; ENZYME ACTIVATION; MALE; MICE; RHO GTP-BINDING PROTEINS;

EID: 55249114648     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318176fae4     Document Type: Article

References (55)

1. Nowak AK, Lake RA, Robinson BW. Combined chemoimmu-notherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev. 2006;58:975-990.
2. Lake RA, Robinson BW. Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer. 2005;5:397-405.
3. Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8T cells. J Immunol. 2003;170:4905-4913.
4. Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. 2005;65:8059-8064.
5. + T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Res. 2005;65:7000-7006.
6. Buttiglieri S, Galetto A, Forno S, et al. Influence of drug-induced apoptotic death on processing and presentation of tumor antigens by dendritic cells. Int J Cancer. 2003;106:516-520.
7. Galetto A, Buttiglieri S, Forno S, et al. Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells. Anticancer Drugs. 2003;14:833-843.
8. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296-306.
9. Zhong H, Shurin MR, Han B. Optimizing dendritic cell-based immunotherapy for cancer. Expert Rev Vaccines. 2007;6:333-345.
10. Fonteneau JF, Larsson M, Bhardwaj N. Dendritic cell-dead cell interactions: implications and relevance for immunotherapy. J Immunother. 2001;24:294-304.
11. Tacken PJ, de Vries IJ, Torensma R, et al. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol. 2007;7:790-802.
12. Inzkirweli N, Guckel B, Sohn C, et al. Antigen loading of dendritic cells with apoptotic tumor cell-preparations is superior to that using necrotic cells or tumor lysates. Anticancer Res. 2007;27:2121-2129.
13. Kotera Y, Shimizu K, Mule JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res. 2001;61:8105-8109.
14. Larmonier N, Merino D, Nicolas A, et al. Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading. Apoptosis. 2006;11:1513-1524.
15. Gaipl US, Munoz LE, Rodel F, et al. Modulation of the immune system by dying cells and the phosphatidylserine-ligand annexin A5. Autoimmunity. 2007;40:254-259.
16. Munoz LE, Franz S, Pausch F, et al. The influence on the immunomodulatory effects of dying and dead cells of Annexin V. J Leukoc Biol. 2007;81:6-14.
17. Chaput N, De Botton S, Obeid M, et al. Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. J Mol Med. 2007;85:1069-1076.
18. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050-1059.
19. West MA, Prescott AR, Eskelinen EL, et al. Rac is required for constitutive macropinocytosis by dendritic cells but does not control its downregulation. Curr Biol. 2000;10:839-848.
20. Benvenuti F, Hugues S, Walmsley M, et al. Requirement of Rac1 and Rac2 expression by mature dendritic cells for T cell priming. Science. 2004;305:1150-1153.
21. Shurin GV, Tourkova IL, Chatta GS, et al. Small rho GTPases regulate antigen presentation in dendritic cells. J Immunol. 2005;174:3394-3400.
22. Tourkova IL, Shurin GV, Wei S, et al. Small rho GTPases mediate tumor-induced inhibition of endocytic activity of dendritic cells. J Immunol. 2007;178:7787-7793.
23. Leverrier Y, Ridley AJ. Requirement for Rho GTPases and PI 3-kinases during apoptotic cell phagocytosis by macrophages. Curr Biol. 2001;11:195-199.
24. Tosello-Trampont AC, Nakada-Tsukui K, Ravichandran KS. Engulfment of apoptotic cells is negatively regulated by Rhomediated signaling. J Biol Chem. 2003;278:49911-49919.
25. Kerksiek KM, Niedergang F, Chavrier P, et al. Selective Rac1 inhibition in dendritic cells diminishes apoptotic cell uptake and cross-presentation in vivo. Blood. 2005;105:742-749.
26. Nakaya M, Tanaka M, Okabe Y, et al. Opposite effects of rho family GTPases on engulfment of apoptotic cells by macrophages. J Biol Chem. 2006;281:8836-8842.
27. Finkielstein CV, Overduin M, Capelluto DG. Cell migration and signaling specificity is determined by the phosphatidylser-ine recognition motif of Rac1. J Biol Chem. 2006;281: 27317-27326.
28. Hoffmann PR, deCathelineau AM, Ogden CA, et al. Phosphatidylserine (PS) induces PS receptor-mediated macropinocytosis and promotes clearance of apoptotic cells. J Cell Biol. 2001;155: 649-659.
29. Zhong H, Han B, Tourkova IL, et al. Low-dose Paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin Cancer Res. 2007;13:5455-5462.
30. Chardin P. Function and regulation of Rnd proteins. Nat Rev Mol Cell Biol. 2006;7:54-62.
31. Narumiya S. The small GTPase Rho: cellular functions and signal transduction. J Biochem. 1996;120:215-228.
32. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997;11:2295-2322.
33. Sahai E, Marshall CJ. Rho-GTPases and cancer. Nat Rev Cancer. 2002;2:133-142.
34. Villalonga P, Guasch RM, Riento K, et al. RhoE inhibits cell cycle progression and Ras-induced transformation. Mol Cell Biol. 2004;24: 7829-7840.
35. Riento K, Villalonga P, Garg R, et al. Function and regulation of RhoE. Biochem Soc Trans. 2005;33:649-651.
36. Villalonga P, Ridley AJ. Rho GTPases and cell cycle control. Growth Factors. 2006;24:159-164.
37. Riento K, Ridley AJ. Inhibition of ROCK by RhoE. Methods Enzymol. 2006;406:533-541.
38. Kobayashi M, Azuma E, Ido M, et al. A pivotal role of Rho GTPase in the regulation of morphology and function of dendritic cells. J Immunol. 2001;167:3585-3591.
39. Swetman CA, Leverrier Y, Garg R, et al. Extension, retraction and contraction in the formation of a dendritic cell dendrite: distinct roles for Rho GTPases. Eur J Immunol. 2002;32:2074-2083.
40. Guasch RM, Blanco AM, Perez-Arago A, et al. RhoE participates in the stimulation of the inflammatory response induced by ethanol in astrocytes. Exp Cell Res. 2007;313:3779-3788.
41. Boswell SA, Ongusaha PP, Nghiem P, et al. The protective role of a small GTPase RhoE against UVB-induced DNA damage in keratinocytes. J Biol Chem. 2007;282:4850-4858.
42. Zhang B, Zhang Y, Dagher MC, et al. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Res. 2005;65:6054-6062.
43. Gnad R, Kaina B, Fritz G. Rho GTPases are involved in the regulation of NF-kappaB by genotoxic stress. Exp Cell Res. 2001; 264:244-249.
44. Liu JY, Wu Y, Zhang XS, et al. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother. 2007;56:1597-1604.
45. Tong Y, Song W, Crystal RG. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res. 2001;61: 7530-7535.
46. Bauer C, Bauernfeind F, Sterzik A, et al. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model. Gut. 2007;56: 1275-1282.
47. Park SD, Kim CH, Kim CK, et al. Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model. Vaccine. 2007;25:3485-3491.
48. Ehrke MJ, Verstovsek S, Maccubbin DL, et al. Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C57BL/6 mice. Int J Cancer. 2000;87:101-109.
49. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202:1691-1701.
50. Ribas A, Timmerman JM, Butterfield LH, et al. Determinant spreading and tumor responses after peptide-based cancer immu-notherapy. Trends Immunol. 2003;24:58-61.
51. Lotze MT, DeMarco RA. Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs. 2003;4: 1405-1409.
52. Dong Xda E, Ito N, Lotze MT, et al. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother (1997). 2007;30:596-606.
53. Ellerman JE, Brown CK, de Vera M, et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 2007;13: 2836-2848.
54. Apetoh L, Ghiringhelli F, Tesniere A, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007;220:47-59.
55. Perrotta C, Bizzozero L, Falcone S, et al. Nitric oxide boosts chemoimmunotherapy via inhibition of acid sphingomyelinase in a mouse model of melanoma. Cancer Res. 2007;67:7559-7564.